CoChat

Angioedema due to angiotensin-converting enzyme inhibitors

Agostoni, Angelo, Cicardi, Marco, Cugno, Massimo, Zingale, Lorenza C, Gioffré, Daniela, Nussberger, Jürg · 1999 · Immunopharmacology

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Angiotensin-converting enzyme (ACE) inhibitor associated angioedema was detected in 39 subjects (17%) of 231 consecutive patients examined in the last 5 years at our out-patient clinic for symptoms of angioedema without urticaria. In these patients, angioedema was most commonly localized to the face. The duration of ACE-inhibitor treatment at the onset of angioedema ranged from 1 day to 8 years with a median of 6 months. The time elapsed between onset of angioedema and withdrawal of ACE-inhibitor ranged from 1 day to 10 years with a median of 10 months. Delayed diagnosis is explained by the unusual characteristics of this adverse reaction: angioedema may start years after beginning the treatment and then it recurs irregularly. In fact, ACE-inhibitors seem to facilitate angioedema in predisposed subjects, rather than causing it with an allergic or idiosyncratic mechanism. Thus, while Cl-inhibitor levels are usually normal in subjects developing ACE-inhibitor-dependent angioedema, we found that ACE-inhibitors caused angioedema in Cl-inhibitor-deficient patients. Because the main inactivator of bradykinin is kininase II, which is identical with ACE, it is believed that bradykinin mediates ACE-inhibitor-dependent angioedema. We had the possibility to examine the plasma bradykinin levels in one ACE-inhibitor-treated patient during an angioedema attack and we found very high levels, but we did not find an increase of break-down products of high-molecular-weight-kininogen as observed during acute attacks in hereditary angioedema. Bradykinin fell to normal levels during remission after withdrawal of the drug. These observations indicate that in ACE-inhibitor-induced angioedema, contrary to hereditary angioedema, the reduction of bradykinin catabolic rate plays a predominant role.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0162-3109(99)00107-1

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

See all 147

Metadata

Authors
Agostoni, A., Cicardi, M., Cugno, M., Zingale, L. C., Gioffré, D., & Nussberger, J.
Affiliations
  • University of Milan (IT)
  • Centre Hospitalier Universitaire Vaudois (CH)
Corresponding author
Agostoni, Angelo
Venue
Immunopharmacology
Publisher
Elsevier BV
Published
1999-10
Volume
44
Issue
1-2
Pages
21-25
ISSN
0162-3109 (ISSN-L)
OpenAlex
W1991493178
Cited by
147
References
21
Citations by year
2025: 6 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 7 · 2015: 4 · 2014: 8 · 2013: 5 · 2012: 6
FWCI
4.37
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Immunopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
Keywords
ACE inhibitors, drug-induced angioedema, bradykinin, C1 inhibitor deficiency, hereditary angioedema, angiotensin-converting enzyme, high molecular weight kininogen, adverse drug reactions, delayed diagnosis
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Angioedema, Angiotensin-Converting Enzyme Inhibitors, Child, Child, Preschool, Female, Heart Failure, Humans, Hypertension, Male, Middle Aged, Recurrence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Angioedema due to angiotensin-converting enzyme inhibitors. https://app.cochat.ai/papers/10.1016/s0162-3109(99)00107-1
The paper
Agostoni, A., Cicardi, M., Cugno, M., Zingale, L. C., Gioffré, D., & Nussberger, J. (1999). Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology. https://doi.org/10.1016/s0162-3109(99)00107-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.